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RON receptor is one member of the MET family of receptor tyrosine kinases. 
When it is activated by its own ligand, macrophage stimulating protein (MSP), RON 
initiates a downstream signaling pathways which result of some function in the cell 
such as dissociation, migration, and invasion. Several RON variants that arise through 
mRNA splicing or by an alternate translational start site have been identified, some 
with oncogenic potential. The purpose of the present project was to determine the 
expression of RON receptor in two breast cancer cell lines since it is the most common 
distribution cancer in women around the world. MDA-MB-213 and MCF-7 breast 
cancer cell lines and WRL-68 embryonic liver as a normal cell line were used in this 
experiment to characterize the expression. The expression of RON receptor on the cell 
surface, the concentration of mRNA and the RON protein were done by utilizing 
Immunofluorescent staining (IF), polymerase chain reaction (PCR) and sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) respectively. 
Collectively, it was found that RON receptor was overexpressed in these two breast 








Reseptor RON adalah sebahagian ahli keluarga MET daripada reseptor 
kinases tyrosina. Apabila RON diaktifkan oleh ligannya sendiri, protein perangsang 
makrofaj (MSP), RON memulakan isyarat tapak jalan hiliran yang menyebabkan 
beberapa fungsi sel seperti penceraian, migrasi dan pencerobohan. Beberapa varian 
RON muncul hasil daripada proses penyuntingan mRNA atau oleh tapak permulaan 
translasi alternatif telah dikenal pasti, setengahnya berpotensi sebagai oncogenic. 
Tujuan projek ini adalah untuk menentukan ekpressi reseptor RON pada sel kanser 
payu dara kerana ia merupakan kanser yang paling biasa tersebar di kalangan wanita 
di seluruh dunia. MDA-MB-213 dan MCF-7 adalah sel kanser payudara dan WRL-
68 adalah sel hati embrio sebagai sel normal telah digunakan dalam eksperimen ini 
untuk mencirikan ekspresi. Ekpresi reseptor RON pada permukaan sel, kepekatan 
mRNA dan protien RON telah dilakukan dengan menggunakan immunofluorescent 
(IF), tindak balas rantaian polimerase (PCR) dan natrium sulfat dodesil 
polyacrylamide gel elektroforesis (SDS-PAGE). Secara kolektifnya, telah didapati 
bahawa reseptor RON adalah terlebih ekspress dalam kedua-dua sel kanser payu 
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1.1 General Introduction 
Cancer is a group of several linked diseases. All kinds of cancer share 
similarity in the growth and extend of abnormal tissues and cells. Progression of 
cancer can be regulated by biomarkers including oncogenesis and tumor suppressor 
genes (American Cancer Society). RON receptor shows a role in cancer metastasis and 
progression by the enlargement of their expression between itself and its ligand named 
as Macrophage Stimulating Protein (MSP). 
RON (Receptuer d'Origine Nantaise) is one of the members that belong to the 
RTKs (Receptors Tyrosine Kinase) family of Met proto-oncogene, which is 
hepatocyte growth factor receptor, containing c Met, c-Sea and Stk. The hepatocyte 
growth factor receptor (HGF; or scatter factor) is related with a lot of processes that 
connected to tumor development and cell survival. 
All RTKs (Receptors Tyrosine Kinase) have quite similar architecture of the 
molecules, with ligand domains binding in the extracellular area, a single 
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transmembrane helix, and a cytoplasmic region that contains the protein tyrosine 
kinase (TK) domain with additional carboxy (C-) terminal and juxtamembrane 
regulatory regions (Lemmon and Schlessinger, 2010).  
RON is involved in the tumor progression and metastasis. It is a protein of 
180-kDa shaped as a heterodimer of two main chains: a 40-kDa α-chain and a 150-
kDa β-chain (Camp et al., 2005).  
RON is originally created as a precursor of a single-chain and pro-RON, and 
then it separates into the two active chains. The first chain (α-chain) is a wholly 
extracellular, and the second chain (β-chain) cut off into the cell membrane and has 
the intracellular tyrosine kinase and regulatory basic elements. RON and c- Met are 
considered to be the only RTKs (Receptors Tyrosine Kinase) that have a Sema domain 
in the protein extracellular part (a stretch of ∼500 amino acids with several highly 
conserved cysteine residues). This domain has a conserved region of amino acid 
sequences, cysteine residues and a potential glycolsylation site. It intercedes a lot of 
signaling cascades that relate to the motility of cells, proliferation, adhesion, and 
apoptosis. 
Macrophage Stimulating Protein (MSP), which is a RON ligand, was initially 
known as a serum protein that stimulate murine resident peritoneal, the chemotaxis of 
the macrophage in response to complement factor C5a. Moreover, MSP is a 
heterodimer of 80-kDa composed of a 53-kDa α-chain and a 30-kDa β-chain linked by 
a disulfide bond. MSP is also known as HGF-like protein (hepatocyte growth factor) 
or scatter factor that belongs to the family of plasminogen-prothrombin gene that 
contains plasminogen and HGF, with others (Camp et al., 2005). 
Mature MSP plays on a group of cell types such as epithelia, macrophages, and 
hematopoietic cells. The actions of macrophages involve activation of movement, 
 3 
creation of phagocytosis of the erythrocytes which is serum complement-coated, 
discouragement of the ability of incitement to synthase up-regulation by swelling 
activation, and stimulation of interleukin-6 (IL-6) secretions.  
It was found that RON expression is not related with sex, age, or disease and 
also found to positively correlate with lymph node metastasis like perigastric lymph 
node metastasis. Previous studies have even publicized that RON expression attaches 
with the invasion of tumor cells (Zhou et al., 2008). 
1.2 Problem Statement  
Previous studies showed that the development of cancer cells associated with 
the expression of the RON receptor in cells. Therefore, determination of RON receptor 
and its expression can be used as an indicator for the progression of the cancer cells. 
1.3 Research Objectives 
The main purpose of this study is to determine the expression of RON 
receptor on breast cancer cell lines by using: Indirect Immunofluorescent Staining 
(IF), Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) and 
Polymerase Chain Reaction (PCR). 

1.4 Scope of Study 
This study is going to be focused on the RON receptor expression on the 
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